• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

by Jasmine Pennic 08/25/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Mira, a hormonal health company, has launched Ultra4™, the first at-home hormone monitor to provide lab-quality insights.

– The new device tracks four key hormones—FSH, LH, E3G, and PdG—with a single wand and a 16-minute test. For the first time, people can monitor their entire cycle from home, from ovulation strength to hormonal balance, with the same precision previously available only in clinics.

Why Tracking Four Hormones Matters

Ultra4™’s technology tracks FSH, LH, E3G, and PdG simultaneously, providing a complete hormonal profile that adapts to each user’s unique biology. By tracking all four hormones across the entire cycle, not just the fertile window, Mira gives users a more complete picture of their hormonal health. This helps users spot irregularities, identify imbalances, monitor shifts over time, and understand their reproductive journey, whether they are trying to conceive, managing PCOS, or approaching menopause.

How Ultra4™ Delivers Lab-Quality Results at Home

Ultra4™ is the only tracker on the market powered by fluorescent technology, the same technology used in clinical laboratories. This gives the device up to seven times the accuracy of other fertility trackers on the market. It is also highly sensitive, capable of detecting subtle hormonal shifts that many other consumer devices miss. The device also offers users the flexibility to test any day of their cycle, or multiple times a day if needed, with guidance from Mira’s AI-powered app.

The product introduces new features, including:

  • 4D Ovulation Profiling™: Models the full hormonal ecosystem to assess when ovulation may occur and its viability.
  • Hormonal Fingerprint™: Creates a personalized baseline of a user’s hormone trends over time to help flag irregularities or early signs of perimenopause.
  • Egg Count Intelligence™: Tracks FSH daily to provide at-home insights into egg health and ovarian reserve.

“When we launched Mira, it was with a single hormone and a single goal: help women understand their fertility better,” said Sylvia Kang, CEO and Co-founder of Mira. “But users kept asking harder questions – about irregular cycles, missed ovulation, egg quality, hormonal balance. Ultra4 is our answer to those questions. It reflects everything we’ve learned in the past seven years from listening to our community.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Femtech

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |